FrancophonIA/ELRC3.0 huggingface dataset:
English: Nasonex is an anti-inflammatory medicine that is used in adults and children from three years of age to treat the symptoms of seasonal allergic or perennial rhinitis (inflammation of the nasal passages caused by occasional or long-term allergy).
Estonian: Nasonex on põletikuvastane ravim, mida kasutatakse täiskasvanutel ja lastel alates 3. eluaastast sesoonse allergilise või püsiva riniidi (episoodilisest või pikaajalisest allergiast põhjustatud ninaõõnepõletik) sümptomite raviks.
English: • Treatment of nasal polyps in adults (aged 18 years and older).
Estonian: • ninapolüüpide ravi täiskasvanutel (alates 18. eluaastast).
English: After reviewing the available data supporting the medicine's use, the CHMP agreed that Nasonex can be used for the following:
Estonian: Ravimi kasutamist toetavate andmete läbivaatamise järel nõustus inimravimite komitee, et Nasonexi tohib kasutada järgmistel näidustustel:
English: In view of this, on 17 September 2013 the European Commission referred the matter to the CHMP in order to harmonise the marketing authorisations for Nasonex in the EU.
Estonian: Seepärast tegi Euroopa Komisjon 17. septembril 2013 inimravimite komiteele esildise Nasonexi müügilubade ühtlustamiseks Euroopa Liidus.
English: Questions and answers on Nasonex and associated names (mometasone furoate, 50 microgram, nasal spray)
Estonian: Teabedokument Nasonexi ja sarnaste nimetuste (mometasoonfuroaat, 50 mcg, ninasprei) kohta
English: • Patients with known hypersensitivity (allergy) to mometasone furoate or to any other ingredients.
Estonian: • patsiendid, kes on teadaolevalt ülitundlikud (allergilised) mometasoonfuroaadi või mis tahes muu koostisaine suhtes;
English: • Treatment of symptoms of seasonal allergic or perennial rhinitis in adults and in children aged three and above.
Estonian: • sesoonse allergilise või püsiva riniidi sümptomite ravi täiskasvanutel ja lastel alates 3. eluaastast;
English: On 20 November 2014, the European Medicines Agency completed a review of Nasonex and associated names.
Estonian: 20. novembril 2014 valmis Euroopa Ravimiametil Nasonexi ja sarnaste nimetuste kohta tehtud taotluse läbivaatamine.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that there is a need to harmonise the prescribing information for Nasonex and associated names in the European Union (EU).
Estonian: Ravimiameti inimravimite komitee järeldas, et Nasonexi ja sarnaste nimetuste määramise teave tuleb Euroopa Liidus (EL) ühtlustada.
English: As Nasonex has been authorised in the EU via national procedures, this has led to divergences across Member States in the way the medicine can be used, as seen in differences in the summaries of product characteristics (SmPCs), labelling and package leaflets in the countries where the medicine is marketed.
Estonian: Et Nasonex on Euroopa Liidus heaks kiidetud riiklike menetluste kaudu, ei ühti ravimit turustavates liikmesriikides ravimi näidustused, mistõttu eri riikides on ravimi omaduste kokkuvõte, märgistus ja pakendi infoleht erinevad.
English: In addition, it is used in adults to treat nasal polyps (growths in the lining of the nose).
Estonian: Lisaks kasutatakse seda täiskasvanutel ninapolüüpide (nina limaskesta vohandid) raviks.
English: Having harmonised the indications, the CHMP also harmonised recommendations on the doses.
Estonian: Pärast näidustuste ühtlustamist ühtlustas inimravimite komitee ka soovitatavad annused.
English: • Patients who have an untreated and localised infection, such as herpes, affecting the inside of the nose.
Estonian: • patsiendid, kellel on ninaõõnes ravimata lokaliseerunud infektsioon, nt herpes;
English: • Patients who have recently undergone nose surgery or who have a wound in the nose, because
Estonian: • patsiendid, kellel on olnud hiljuti ninaoperatsioon või kellel on ninas haav, sest Nasonex võib mõjutada haava paranemist.
English: The CHMP agreed to that Nasonex must not be used in:
Estonian: Inimravimite komitee nõustus, et Nasonexi ei tohi kasutada järgmistel patsientidel:
English: The CHMP, in the light of the data submitted and the scientific discussion within the Committee, was of the opinion that the SmPCs, labelling and package leaflets for Nasonex should be harmonised across the EU.
Estonian: Esitatud andmete hindamise ja komitees toimunud teadusliku arutelu põhjal järeldas inimravimite komitee, et Nasonexi ravimi omaduste kokkuvõtted, märgistus ja pakendi infolehed tuleb Euroopa Liidus ühtlustada.
English: The labelling and package leaflet were also revised in line with the changes to the SmPC.
Estonian: Kooskõlas ravimi omaduste kokkuvõttesse tehtud muudatustega vaadati üle ka märgistus ja pakendi infoleht.
English: It is available as a nasal spray.
Estonian: Seda turustatakse ninaspreina.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Rasilez on 22 August 2007.
Estonian: Euroopa Komisjon andis Rasilezi müügiloa, mis kehtib kogu Euroopa Liidus, 22. augustil 2007.
English: Rasilez aliskiren
Estonian: Rasilez aliskireen
English: This summary was last updated in 06-2016.
Estonian: Kokkuvõtte viimane uuendus: 06-2016.
English: What measures are being taken to ensure the safe and effective use of Rasilez?
Estonian: Mis meetmed võetakse, et tagada Rasilezi ohutu ja efektiivne kasutamine?
English: The medicine's effects were maintained for up to a year in two of the studies.
Estonian: Ravimi toime püsis kahes uuringus kuni ühe aasta.
English: It is available as tablets (150 and 300 mg).
Estonian: Seda turustatakse tablettidena (150 ja 300 mg).
English: Other information about Rasilez
Estonian: Muu teave Rasilezi kohta
English: The full EPAR for Rasilez can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Rasilezi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: Rasilez is for use in adults only; it must not be used in children aged less than 2 years and is not recommended for older children.
Estonian: Rasilez on ette nähtud ainult täiskasvanutele; seda ei tohi kasutada alla 2-aastased lapsed ja seda ei soovitata vanematele lastele.
English: Its use during the first three months of pregnancy and in women planning to become pregnant is not recommended.
Estonian: Raseduse esimesel kolmel kuul ja rasestuda kavatsevatel naistel ei ole ravimi kasutamine soovitatav.
English: The recommended dose of Rasilez is 150 mg once a day.
Estonian: Rasilezi soovituslik annus on 150 mg üks kord ööpäevas.
English: Rasilez has been studied in 14 main studies involving over 10,000 patients with essential hypertension.
Estonian: Rasilezi kasutamist uuriti 14 põhiuuringus, milles osales üle 10 000 essentsiaalse hüpertensiooniga patsiendi.
English: The CHMP therefore decided that the benefits of Rasilez are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas seetõttu, et Rasilezi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Rasilez have also been included in the summary of product characteristics and the package leaflet.
Estonian: Rasilezi ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on samuti lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: When the results of the five studies comparing Rasilez taken alone with placebo were looked at together, patients aged under 65 years had an average fall in diastolic blood pressure of 9.0 mmHg after eight weeks of taking 150 mg Rasilez, from an average of 99.4 mmHg at the start of the study.
Estonian: Viie uuringu kokkuvõttes, milles võrreldi Rasilezi kasutamist ainsa ravimina platseebo kasutamisega, vähenes alla 65-aastaste patsientide diastoolne vererõhk pärast 150 mg Rasilezi kasutamist kaheksa nädala jooksul keskmiselt 9,0 mm Hg võrra, võrreldes keskmise rõhuga 99,4 mm Hg ravi algul.
English: Rasilez also reduced blood pressure in patients with diabetes and patients who were overweight.
Estonian: Rasilez vähendas vererõhku ka diabeediga ja ülekaalulistel patsientidel.
English: For more information about treatment with Rasilez, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Rasileziga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Rasilez is used to treat essential hypertension (high blood pressure) in adults.
Estonian: Rasilezi kasutatakse essentsiaalse hüpertensiooni (kõrgvererõhutõve) ravimiseks täiskasvanutel.
English: Rasilez is a medicine that contains the active substance aliskiren.
Estonian: Rasilez on ravim, mis sisaldab toimeainena aliskireeni.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Rasilez.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: By blocking the production of angiotensin I, levels of both angiotensin I and angiotensin II fall.
Estonian: Angiotensiin I tekke blokeerimisega väheneb nii angiotensiin I kui ka angiotensiin II sisaldus veres.
English: This is a summary of the European public assessment report (EPAR) for Rasilez.
Estonian: See on ravimi Rasilez Euroopa avaliku hindamisaruande kokkuvõte.
English: Why has Rasilez been approved?
Estonian: Miks Rasilez heaks kiideti?
English: The studies with Rasilez taken in combination with other medicines showed additional decreases in blood pressure compared with the decreases produced by these medicines alone.
Estonian: Uuringud, milles Rasilezi kasutati koos teiste ravimitega, näitasid vererõhu lisavähenemist võrreldes sellega, kui samu ravimeid kasutati üksi.
English: Rasilez should not be taken together with fruit juice or drinks containing plant extracts such as herbal teas.
Estonian: Rasilezi manustamise ajal ei tohi juua puuviljamahla ega taimeekstrakte sisaldavaid jooke, näiteks taimeteed.
English: What is Rasilez?
Estonian: Mis on Rasilez?
English: The studies lasted between six and 52 weeks and the main measure of effectiveness was the change in blood pressure during either the resting phase of the heartbeat (‘diastolic') or when the chambers of the heart were contracting (‘systolic').
Estonian: Uuringud kestsid 6-52 nädalat ja nende efektiivsuse põhinäitaja oli diastoolse (nn alumise) või süstoolse (nn ülemise) vererõhu muutus.
English: What is the risk associated with Rasilez?
Estonian: Mis riskid Rasileziga kaasnevad?
English: Rasilez must not be used in patients who have had angioedema (swelling under the skin) with aliskiren, hereditary angioedema or angioedema of no obvious cause, or in women who are more than three months pregnant.
Estonian: Rasilezi ei tohi kasutada patsiendid, kellel on olnud aliskireeni kasutamisel angioödeem (nahaalune turse), pärilik angioödeem või teadmata põhjusega angioödeem, ega rasedad pärast esimest kolme raseduskuud.
English: The blood pressure was measured in ‘millimetres of mercury' (mmHg).
Estonian: Vererõhu ühik oli millimeetrit elavhõbedasammast (mm Hg).
English: In five of the studies, the effects of Rasilez taken alone were compared with those of placebo (a dummy treatment).
Estonian: Viies uuringus võrreldi Rasilezi toimet selle kasutamisel ainsa ravimina platseebo (näiva ravimi) toimega.
English: Rasilez, taken alone or in combination with other medicines, was also compared with other medicines for hypertension.
Estonian: Rasilezi toimet ainsa ravimina või koos teiste ravimitega kasutamisel võrreldi ka teiste kõrgvererõhuravimite toimega.
English: Angiotensin I is converted into the hormone angiotensin II, which is a powerful vasoconstrictor (a substance that narrows blood vessels).
Estonian: Angiotensiin I muundub hormooniks angiotensiin II, mis on tugeva toimega vasokonstriktor (veresooni ahendav aine).
English: For the full list of all side effects reported with Rasilez, see the package leaflet.
Estonian: Rasilezi kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: The most common side effects with Rasilez (seen in between 1 and 10 patients in 100) are dizziness, diarrhoea, arthralgia (joint pain) and hyperkalaemia (high blood potassium levels).
Estonian: Rasilezi kõige sagedamad kõrvalnähud (esinenud 1-10 patsiendil 100st) on peapööritus, kõhulahtisus, artralgia (liigesevalu) ja hüperkaleemia (kaaliumi suur sisaldus veres).
English: Thirteen of the studies included patients with mild to moderate hypertension, and one included patients with severe hypertension.
Estonian: 13 uuringus osalesid kerge või mõõduka hüpertensiooniga ja ühes raske hüpertensiooniga patsiendid.
English: Combination studies looked at Rasilez used with an ACE inhibitor (ramipril), an ARB (valsartan), a beta-blocker (atenolol), a calcium-channel blocker (amlodipine) and a diuretic (hydrochlorothiazide).
Estonian: Ravimikombinatsioonide uuringutes vaadeldi Rasilezi kasutamist koos ACE-inhibiitoriga (ramipriil), ARB-ga (valsartaan), beetablokaatoriga (atenolool), kaltsiumikanali blokaatoriga (amlodipiin) ja diureetikumiga (hüdroklorotiasiid).
English: What benefit has Rasilez shown during the studies?
Estonian: Milles seisneb uuringute põhjal Rasilezi kasulikkus?
English: Rasilez must also not be taken with ciclosporin, itraconazole or other medicines known as ‘potent P-glycoprotein inhibitors' (such as quinidine).
Estonian: Rasilezi ei tohi võtta koos tsüklosporiini, itrakonasooli ja teiste tugevate Pglükoproteiini inhibiitoritega (nt kinidiiniga).
English: Rasilez may be taken alone or in combination with other medicines for hypertension, with the exception of ‘angiotensin converting enzyme (ACE) inhibitors' or ‘angiotensin receptor blockers' (ARBs) in patients with diabetes, or moderate or severe kidney impairment.
Estonian: Rasilezi tohib kasutada ainsa ravimina või koos teiste kõrgvererõhuravimitega, v.a angiotensiini muundava ensüümi (ACE) inhibiitorite või angiotensiini retseptori blokaatoritega (ARB), kui patsiendil on diabeet või mõõdukas kuni raske neerukahjustus.
English: Rasilez in combination with an ACE inhibitor or an ARB must not be used in patients with diabetes, or moderate or severe kidney impairment.
Estonian: Rasilezi ei tohi kasutada koos ACE-inhibiitori ega ARB-ga, kui patsiendil on diabeet või mõõdukas kuni raske neerukahjustus.
English: This was compared with a fall of 5.8 mmHg from 99.3 mmHg in the patients taking placebo.
Estonian: Tulemust võrreldi platseebot kasutanud patsientide vererõhuga, mis vähenes 5,8 mm Hg võrra (ravi algul keskmiselt 99,3 mm Hg).
English: What is Rasilez used for?
Estonian: Milleks Rasilezi kasutatakse?
English: This may reduce the risks associated with high blood pressure, such as having a stroke.
Estonian: Selle tulemusena veresooned laienevad ja vererõhk langeb ning vähenevad kõrgvererõhuga seotud riskid, näiteks insuldi risk.
English: How is Rasilez used?
Estonian: Kuidas Rasilezi kasutatakse?
English: How does Rasilez work?
Estonian: Kuidas Rasilez toimib?
English: It blocks the activity of a human enzyme called renin, which is involved in the production of a substance called angiotensin I in the body.
Estonian: Rasilezi toimeaine aliskireen on reniini inhibiitor ehk aine, mis blokeerib organismis angiotensiin I tekkes osaleva inimensüümi reniini toime.
English: The dose of Rasilez may be increased to 300 mg once a day in patients whose blood pressure is not adequately controlled.
Estonian: Patsientidel, kelle vererõhk ravile piisavalt ei allu, võib Rasilezi annust suurendada kuni 300 mg üks kord ööpäevas.
English: Larger falls were seen in patients aged 65 years or over and those taking higher doses of Rasilez.
Estonian: Vähemalt 65-aastastel patsientidel ja Rasilezi suuremates annustes kasutanud patsientidel vähenes vererõhk rohkem.
English: The CHMP noted that Rasilez is effective in reducing blood pressure when used alone or in combination.
Estonian: Inimravimite komitee märkis, et Rasilez on vererõhu alandamisel efektiivne ainuravimina või koos teiste ravimitega.
English: However, in February 2012, following the review of a study called ALTITUDE, the CHMP recommended that Rasilez should not be used together with an ACE inhibitor or ARB in patients with diabetes or with moderate or severe kidney impairment because of an increase in the risk of cardiovascular and kidney problems.
Estonian: tulemuste läbivaatamist soovitas inimravimite komitee Rasilezi mitte kasutada koos ACE-inhibiitori ega ARB-ga patsientidel, kellel on diabeet või mõõdukas kuni raske neerukahjustus, sest ravim suurendab kardiovaskulaarsete ja neeruhäirete riski.
English: How has Rasilez been studied?
Estonian: Kuidas Rasilezi uuriti?
English: Rasilez on its own was more effective than placebo and as effective as comparator treatments in reducing blood pressure.
Estonian: Rasilez vähendas kasutamisel ainsa ravimina vererõhku efektiivsemalt kui platseebo ja sama efektiivselt kui võrdlusravimid.
English: The medicine can only be obtained with a prescription.
Estonian: Rasilez on retseptiravim.
English: Each study lasted three to four months.
Estonian: Iga uuring kestis 3-4 kuud.
English: In the context of a procedure under Article 20 of Regulation (EC) No 726/2004.
Estonian: Määruse (EÜ) nr 726/2004 artikli 20 kohase menetluse raames.
English: This overview was last updated in 11-2018.
Estonian: Kokkuvõtte viimane uuendus: 11.2018.
English: Corlentor received a marketing authorisation valid throughout the EU on 25 October 2005.
Estonian: Corlentor on saanud müügiloa, mis kehtib kogu ELis, 25. oktoobril 2005.
English: More information can be found here.
Estonian: Lisateave on siin.
English: Corlentor must not be taken with a number of other medicines.
Estonian: Corlentorit ei tohi kasutada koos teatavate teiste ravimitega.
English: What measures are being taken to ensure the safe and effective use of Corlentor?
Estonian: Mis meetmed võetakse, et tagada Corlentori ohutu ja efektiivne kasutamine?
English: Further information on Corlentor can be found on the Agency's website: https://www.ema.europa.eu/en/medicines/human/EPAR/corlentor
Estonian: Lisateave Corlentori kohta on ameti veebilehel: https://www.ema.europa.eu/en/medicines/human/EPAR/corlentor
English: Other information about Corlentor
Estonian: Muu teave Corlentori kohta
English: Corlentor (ivabradine)
Estonian: Corlentor (ivabradiin)
English: As for all medicines, data on the use of Corlentor are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse Corlentori kasutamise kohta pidevat järelevalvet.
English: The Agency decided that Corlentor's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Corlentori kasulikkus on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise võib ELis heaks kiita.
English: What is Corlentor and what is it used for?
Estonian: Mis on Corlentor ja milleks seda kasutatakse?
English: Side effects reported with Corlentor are carefully evaluated and any necessary action taken to protect patients.
Estonian: Corlentori kõrvalnähte hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: Angina
Estonian: Stenokardia
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Corlentor have been included in the summary of product characteristics and the package leaflet.
Estonian: Corlentori ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: However it should be noted that patients in this study were given doses higher than the recommended dose (up to 10 mg twice a day).
Estonian: Tuleb aga märkida, et selles uuringus osalenud patsiendid kasutasid soovitatavast annusest suuremaid annuseid (kuni 10 mg kaks korda ööpäevas).
English: For more information about using Corlentor, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Corlentori kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: Corlentor contains the active substance ivabradine.
Estonian: Corlentor sisaldab toimeainena ivabradiini.
English: The main measure of effectiveness was how long patients could exercise on a bicycle or a treadmill, which was measured at the start and the end of each study.
Estonian: Efektiivsuse põhinäitaja oli patsientide füüsilise koormuse suurim kestus jalgrattal või jooksulindil, mõõdetuna uuringu alguses ja lõpus.
English: In patients over 75 years old, a lower starting dose of 2.5 mg twice a day can be used.
Estonian: Üle 75-aastastel patsientidel võib kasutada väiksemat algannust, 2,5 mg kaks korda ööpäevas.
English: In stable angina, these symptoms appear during physical effort.
Estonian: Stabiilse stenokardia korral tekivad sümptomid füüsilise pingutuse tagajärjel.
English: The main measure of effectiveness was a reduction in the risk of death due to heart problems and non-fatal heart attack.
Estonian: Efektiivsuse põhinäitaja oli kardiovaskulaarse surma ja mittefataalse südameinfarkti riski vähenemine.
English: However, a fifth study in 728 patients showed that adding Corlentor to amlodipine did not provide an additional benefit.
Estonian: Seevastu viiendas uuringus, milles osales 728 patsienti, ei suurendanud Corlentori lisamine amlodipiinile ravi kasulikkust.
English: Treatment must be stopped if the heart rate is persistently below 50 beats per minute or if symptoms of bradycardia (slow heart rate) continue despite dose reduction.
Estonian: Ravi tuleb katkestada, kui südame löögisagedus on pidevalt alla 50 löögi minutis või kui bradükardia (aeglane südame löögisagedus) sümptomid jätkuvad vaatamata annuse vähendamisele.
English: It also concluded that Corlentor was effective in long-term heart failure with an acceptable safety profile.
Estonian: Amet järeldas ka, et Corlentor on efektiivne pikaajalise südamepuudulikkuse ravis ja selle ohutusprofiil on vastuvõetav.
English: The European Medicines Agency concluded that Corlentor was shown to be effective in long-term angina with an acceptable safety profile for it to provide an alternative treatment for patients who cannot take beta blockers or whose disease is not controlled with them.
Estonian: Euroopa Ravimiamet järeldas, et Corlentor on pikaajalise stenokardia ravis efektiivne ning selle ohutusprofiil on vastuvõetav kasutamiseks alternatiivse ravimina patsientidel, kelle haigus ei allu ravile beetablokaatoritega või kes ei saa neid kasutada.
English: What are the risks associated with Corlentor?
Estonian: Mis riskid Corlentoriga kaasnevad?
English: When these currents are blocked, the heart rate is lowered, so that the heart has less work to do and needs less oxygenated blood.
Estonian: Kui If-vool on blokeeritud, väheneb südame löögisagedus, süda töötab vähem ja vajab vähem hapnikurikast verd.
English: Corlentor must not be used in patients who have a resting heart rate below 70 beats per minute, very low blood pressure, various types of heart disorder (including cardiogenic shock, rhythm disorders, heart attack, unstable or acute (sudden) heart failure and unstable angina) or severe liver problems.
Estonian: Corlentorit ei tohi kasutada patsiendid, kelle südame löögisagedus on puhkeolekus alla 70 löögi minutis, kellel on väga madal vererõhk, mitmesugused südamehäired (sh kardiogeenne šokk, rütmihäired, südameinfarkt, ebastabiilne või äge (äkiline) südamepuudulikkus ja ebastabiilne stenokardia) või rasked maksaprobleemid.
English: Corlentor is available as tablets (5 and 7.5 mg) and it can only be obtained with a prescription.
Estonian: Corlentorit turustatakse tablettidena (5 ja 7,5 mg).